| 14/03/22 | 07:00:11 | 14 Mar 2022 | | Update on US review of Fasenra in nasal polyps |
| 09/03/22 | 15:30:01 | 9 Mar 2022 | | Director/PDMR Shareholding |
| 07/03/22 | 15:30:01 | 7 Mar 2022 | | Director/PDMR Shareholding |
| 01/03/22 | 15:30:01 | 1 Mar 2022 | | Director/PDMR Shareholding |
| 01/03/22 | 15:00:01 | 1 Mar 2022 | | Total Voting Rights |
| 01/03/22 | 07:00:06 | 1 Mar 2022 | | AstraZeneca and Neurimmune close deal for NI006 |
| 23/02/22 | 07:00:02 | 23 Feb 2022 | | Filing of Form 20-F with SEC |
| 22/02/22 | 11:00:00 | 22 Feb 2022 | | Chair succession planning update and Annual Report |
| 21/02/22 | 07:00:09 | 21 Feb 2022 | | Enhertu improves PFS and OS in HER2-low BC |
| 16/02/22 | 07:00:08 | 16 Feb 2022 | | Saphnelo approved in EU for SLE |
| 15/02/22 | 07:00:06 | 15 Feb 2022 | | Lynparza combo delays progression risk in prostate |
| 11/02/22 | 15:30:02 | 11 Feb 2022 | | Director/PDMR Shareholding |
| 10/02/22 | 07:00:03 | 10 Feb 2022 | | AZN: Full year and Q4 2021 results |
| 01/02/22 | 15:00:05 | 1 Feb 2022 | | Total Voting Rights |
| 19/01/22 | 07:05:08 | 19 Jan 2022 | | Imfinzi improves survival in biliary tract cancer |
| 19/01/22 | 07:00:07 | 19 Jan 2022 | | Imfinzi combo shows unprecedented survival in HCC |
| 17/01/22 | 07:00:07 | 17 Jan 2022 | | Enhertu granted Priority Review for breast cancer |
| 07/01/22 | 07:00:07 | 7 Jan 2022 | | AstraZeneca and Neurimmune sign deal for NI006 |
| 05/01/22 | 07:00:08 | 5 Jan 2022 | | Transfer of rights to Eklira, Duaklir completed |
| 04/01/22 | 15:00:07 | 4 Jan 2022 | | Total Voting Rights |
| 29/12/21 | 07:00:11 | 29 Dec 2021 | | AstraZeneca and Ionis close eplontersen deal |
| 21/12/21 | 07:00:05 | 21 Dec 2021 | | Ultomiris accepted for FDA Priority Review for gMG |
| 20/12/21 | 07:05:06 | 20 Dec 2021 | | Tezspire approved in the US for severe asthma |
| 20/12/21 | 07:00:07 | 20 Dec 2021 | | Saphnelo recommended for EU approval for SLE |
| 15/12/21 | 15:00:01 | 15 Dec 2021 | | Director/PDMR Shareholding |
| 09/12/21 | 07:00:06 | 9 Dec 2021 | | Evusheld US FDA EUA |
| 07/12/21 | 07:00:04 | 7 Dec 2021 | | AstraZeneca, Ionis to collaborate on eplontersen |
| 01/12/21 | 15:00:06 | 1 Dec 2021 | | Block listing Interim Review |
| 01/12/21 | 15:00:06 | 1 Dec 2021 | | Total Voting Rights |
| 30/11/21 | 07:00:06 | 30 Nov 2021 | | Lynparza granted FDA Priority Review for OlympiA |
| 15/11/21 | 16:00:05 | 15 Nov 2021 | | Director/PDMR Shareholding |
| 12/11/21 | 07:00:02 | 12 Nov 2021 | | AZN: Year to date and Q3 2021 results |
| 01/11/21 | 15:00:01 | 1 Nov 2021 | | Total Voting Rights |
| 01/11/21 | 07:00:12 | 1 Nov 2021 | | AstraZeneca to transfer rights to Eklira, Duaklir |
| 25/10/21 | 07:00:14 | 25 Oct 2021 | | Imfinzi improved survival in biliary tract cancer |
| 18/10/21 | 07:00:06 | 18 Oct 2021 | | AZ recommends ADS holders reject mini-tender offer |
| 15/10/21 | 07:00:03 | 15 Oct 2021 | | Imfinzi & tremelimumab improved OS in liver cancer |
| 11/10/21 | 07:00:10 | 11 Oct 2021 | | AZD7442 PhIII trial positive in COVID outpatients |
| 04/10/21 | 07:00:07 | 4 Oct 2021 | | Enhertu granted BTD for breast cancer |
| 01/10/21 | 15:00:02 | 1 Oct 2021 | | Total Voting Rights |
| 30/09/21 | 16:00:07 | 30 Sept 2021 | | Director/PDMR Shareholding |
| 29/09/21 | 07:00:09 | 29 Sept 2021 | | AstraZeneca to fully acquire Caelum Biosciences |
| 28/09/21 | 07:00:05 | 28 Sept 2021 | | Saphnelo approved in Japan for SLE |
| 24/09/21 | 07:00:05 | 24 Sept 2021 | | Lynparza PROpel trial meets primary endpoint |
| 23/09/21 | 07:00:08 | 23 Sept 2021 | | Board Committee Change |
| 23/09/21 | 07:00:08 | 23 Sept 2021 | | New Sustainability Committee of the Board |
| 21/09/21 | 07:00:09 | 21 Sept 2021 | | AstraZeneca $360m Irish manufacturing investment |
| 20/09/21 | 07:00:08 | 20 Sept 2021 | | Enhertu reduced risk of disease progression by 72% |
| 09/09/21 | 16:00:04 | 9 Sept 2021 | | Imfinzi improves survival in NSCLC in POSEIDON |
| 09/09/21 | 07:00:05 | 9 Sept 2021 | | PT027 PhIII asthma trials met primary endpoints |
